SNB-101 / SN BioSci 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  SNB-101 / SN BioSci
    Journal:  Generation of anti-SN38 antibody for loading efficacy and therapeutic monitoring of SN38-containing therapeutics. (Pubmed Central) -  Jul 18, 2024   
    However, it has garnered significant scientific interest as a payload in conjugated nanomedicine platforms (e.g., SN-38lip, NK012, SNB-101, and ADCs) to enhance their effectiveness and safety...The immunization efficiency, reactivity, binding affinity, specificity, and cross-reactivity of purified pAb and mAb against Irinotecan, a model for the emergence of an SN38 derivative in clinical settings, were evaluated using ELISA and western blotting (WB) techniques...The affinity of both pAb and mAb also meets the acceptance criteria for quantifying SN38 in fluidic material, as well as in Therapeutic drug monitoring (TDM) studies, a crucial aspect of personalized medicine. The potential applications of the anti-SN38 antibodies extend to reducing SN38-induced systemic toxicity through an inverse targeting strategy, a novel approach that piques further interest in our findings.
  • ||||||||||  SNB-101 / SN BioSci
    Trial completion date, Trial primary completion date, Metastases:  Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors (clinicaltrials.gov) -  Nov 27, 2023   
    P1,  N=36, Not yet recruiting, 
    The potential applications of the anti-SN38 antibodies extend to reducing SN38-induced systemic toxicity through an inverse targeting strategy, a novel approach that piques further interest in our findings. Trial completion date: Dec 2023 --> Jun 2025 | Trial primary completion date: May 2023 --> Dec 2024
  • ||||||||||  Avastin (bevacizumab) / Roche
    [VIRTUAL] Enhanced anti-tumor effect and tolerance of novel irinotecan (sn-38) nanoparticle with double core-shell micelle technology () -  Mar 13, 2021 - Abstract #AACR2021AACR_4867;    
    As the addition of Bevacizumab to SNB-101 monotherapy is associated with profound inhibition of HT-29 tumor growth progression, the consistent reduction in tumor weights was also observed. Although tolerability of the substance in clinical studies is well known, there are some limitations in correlating the results of pre-clinical models to in-depth comprehension of human model; thus, we hope to further investigate the pharmacological action of SNB-101 in new regimens and indications in the next step - First in Human trial.
  • ||||||||||  SNB-101 / SN BioScience
    Journal:  Novel SN-38 double core-shell micelle formulation, SNB-101, enhanced anti-tumor effect and tolerance. (Pubmed Central) -  Feb 23, 2020   
    Although tolerability of the substance in clinical studies is well known, there are some limitations in correlating the results of pre-clinical models to in-depth comprehension of human model; thus, we hope to further investigate the pharmacological action of SNB-101 in new regimens and indications in the next step - First in Human trial. No abstract available